Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDF
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Rosiglitazone and cardiovascular risk - NPS fact sheetRosiglitazone and cardiovascular risk - NPS fact sheet
Published 2007-08-01 00:00:00
A recent meta-analysis has raised concerns about a potential increase in cardiovascular risk among patients treated with rosiglitazone. NPS has released a fact sheet, Rosiglitazone and cardiovascular risk, which discusses this issue.
Date published: 2007-08-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
